William Blair
http://www.williamblair.comWilliam Blair & Company, L.L.C. is a Chicago-based investment firm offering investment banking, asset management, equity research, institutional and private brokerage, and private capital to individual, institutional, and issuing clients. Since 1935, it has been committed to helping clients achieve their financial objectives.
-
William Blair Reiterates Outperform Rating on VistaGen Therapeutics (VTGN)
-
VistaGen to Participate at William Blair Biotech Focus Conference 2022
-
"PH94B Has Potential to Open Several New Markets" - William Blair Reiterates Outperform Rating on VistaGen Therapeutics (VTGN)
-
VistaGen to Participate in Upcoming June Investor Conferences
-
"PH94B Could Become First Rapid-Onset Treatment for SAD" - William Blair Reiterates Outperform Rating on VistaGen Therapeutics (VTGN)
-
William Blair Reiterates Outperform Rating on VistaGen Therapeutics (VTGN)
-
VistaGen Therapeutics to Participate in William Blair Biotech Focus Conference 2021
-
VistaGen Therapeutics to Participate in William Blair Biotech Focus Conference 2021
-
VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update
-
VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update
-
VistaGen Therapeutics to Present at Two Investor Conferences in June
-
VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021
-
VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021
-
VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering
-
VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering
-
VistaGen Therapeutics (VTGN) Prices Underwritten Public Offering of Common Stock, Conv. Preferred Stock
-
VistaGen Therapeutics Announces Pricing of Underwritten Public Offering
-
VistaGen Therapeutics (VTGN) Announces Proposed Underwritten Public Offering
-
VistaGen Therapeutics Announces Proposed Underwritten Public Offering
-
William Blair Downgrades VistaGen Therapeutics (VTGN) to Market Perform
-
William Blair Starts VistaGen Therapeutics (VTGN) at Outperform
-
VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019
-
VistaGen Therapeutics (VTGN) Prices 10M Share Offering at $1/Sh
-
VistaGen Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
-
VistaGen Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
-
VistaGen Therapeutics (VTGN) to Offer Common Stock
-
VistaGen Therapeutics Announces Proposed Public Offering of Common Stock
-
VistaGen Therapeutics Announces Proposed Public Offering of Common Stock

